🔎 Trials Near Me

Beranda › Kanker Paru › Tennessee › Nashville

Uji klinis Kanker Paru di Nashville, TN

40 studi untuk Kanker Paru mencari peserta di lokasi sekitar Nashville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Menerima pesertaFase 1/2
  • Sarah Cannon Research Institute, Nashville
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Menerima pesertaFase 2
  • SCRI Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06172478

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Menerima pesertaFase 1
  • SCRI Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06625775

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Menerima pesertaFase 3
  • SCRI Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06765109

A Study of PHN-012 in Patients With Advanced Solid Tumors

Menerima pesertaFase 1
  • PHN-012-001 Site, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07127874

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Menerima pesertaFase 3
  • SCRI Oncology Partners - Tennessee, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06881784

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Menerima pesertaFase 1
  • Sarah Cannon Research Institute- Pharmacy, Nashville
  • SCRI Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07519655

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Menerima pesertaFase 3
  • Sarah Cannon Research Institute, Nashville
  • United States Oncology Regulatory Affairs Corporate Office, Nashville
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05920356

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • SCRI Oncology Partners, Nashville
  • Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology, Nashville
  • Tennessee Oncology, PLLC - Saint Thomas West, Nashville
  • dan 3 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07222566

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Menerima pesertaFase 2
  • Sarah Cannon Research Institute, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07154290

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Menerima pesertaFase 2
  • Research Site, Nashville
  • Research Site, Nashville
Usia 18 hingga 95 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Menerima pesertaFase 2/3
  • Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06712316

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Menerima pesertaFase 2/3
  • Tennessee Oncology, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07100080

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Menerima pesertaFase 1/2
  • Sarah Cannon Research Institue, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Menerima pesertaFase 1/2
  • Tennessee Oncology, PLLC, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07629960

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Menerima pesertaFase 1/2
  • Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05786924

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Menerima pesertaFase 1
  • Sarah Cannon Research Institute, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1
  • Sarah Cannon Research Institute, Nashville
  • SCRI Oncology Partners, Nashville
  • Vanderbilt-Ingram Cancer Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06561685

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Menerima pesertaFase 3
  • Tennessee Oncology, Nashville
  • USO - US Oncology Research Network, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Menerima pesertaFase 1
  • SCRI Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06343402

Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

Menerima pesertaStudi observasional
  • Vanderbilt-Ingram Cancer Center, Nashville
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT00897117

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Menerima pesertaFase 1
  • Xencor Investigative Site, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT05433142

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Menerima pesertaFase 1/2
  • Tennessee Oncology, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06162221

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Menerima pesertaFase 1
  • Sarah Cannon, SCRI Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT04678648

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Menerima pesertaFase 1/2
  • Vanderbilt University Medical Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT06051695

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Menerima pesertaFase 1
  • Research Site, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT06835569

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Menerima pesertaFase 1
  • Sarah Cannon Research Institute, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT06040541

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Menerima pesertaFase 1/2
  • Sarah Cannon Research Institute, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Mei 2026 · NCT05379985

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

Menerima pesertaStudi observasional
  • Vanderbilt-Ingram Cancer Center, Nashville
  • Veterans Affairs Medical Center - Nashville, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Apr 2026 · NCT00898313

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Menerima pesertaFase 1/2
  • SCRI Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Apr 2026 · NCT07020221

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1
  • SCRI Oncology Partners, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mar 2026 · NCT05948865

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Menerima pesertaFase 1
  • Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
  • Vanderbilt University Medical Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT06778863

EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

Menerima pesertaFase 4
  • Vanderbilt University/Ingram Cancer Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Feb 2026 · NCT06105801

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Vanderbilt-Ingram Cancer Center, Nashville
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

Menerima pesertaFase 1
  • Sarah Cannon Research Institute (SCRI), Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jan 2026 · NCT07181473

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Menerima pesertaStudi observasional
  • Massive Bio SYNERGY-AI site, Nashville
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Tennessee Oncology, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2025 · NCT05941507

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Menerima pesertaFase 1/2
  • Vanderbilt University/Ingram Cancer Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Okt 2024 · NCT05501665

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

Menerima pesertaFase 1/2
  • Vanderbilt University/Ingram Cancer Center, Nashville
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Jun 2024 · NCT06110572

Uji klinis Kanker Paru di kota lain

Studi lain di Nashville

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.